From the Faculty of Medicine, Ain Shams University, Egypt, Al Noor Hospital, Abu Dhabi, United Arab Emirates.
World Allergy Organ J. 2011 Aug;4(8):130-4. doi: 10.1097/WOX.0b013e31822a6e9a.
: Allergic rhinitis (AR) affects up to 36% of the population in the Middle East Gulf States. The second-generation nonsedating antihistamine desloratadine has demonstrated safety and efficacy in the treatment of AR; however, few studies have evaluated this agent in Arab and Asian populations in the Middle East.
: This open-label study enrolled subjects ≥12 years with moderate-to-severe AR; they received desloratadine 5 mg QD for 2 weeks. Endpoints included change in mean individual nasal and ocular symptom scores, total symptom score (TSS), and peak nasal inspiratory flow (PNIF) and percentage improvement in global response to therapy.
: There were 602 subjects from 5 Middle East countries enrolled. After 2 weeks, desloratadine significantly (P < 0.0001) reduced mean scores for individual nasal and total ocular symptom scores and TSS. PNIF measures of nasal congestion were significantly (P < 0.0001) improved after treatment. Most subjects obtained complete (38.1%) or marked (47.2%) relief of AR symptoms. Treatment failure was reported in 2.2% of subjects. No adverse events were reported, and no subjects discontinued treatment.
: Most subjects reported significant symptom relief with desloratadine 5 mg/d for 2 weeks. Desloratadine is effective in the treatment of AR in Arab and Asian subjects in the Middle East Gulf region.
在中东海湾国家，过敏性鼻炎（AR）影响多达 36%的人群。第二代非镇静抗组胺药地氯雷他定在治疗 AR 方面已被证明具有安全性和有效性；然而，在阿拉伯和亚洲人群中，很少有研究评估该药物在中东的应用。
这项开放标签研究招募了年龄≥12 岁的中重度 AR 患者；他们接受地氯雷他定 5mgQD 治疗 2 周。终点包括平均个体鼻部和眼部症状评分、总症状评分（TSS）、峰值鼻吸气流量（PNIF）和治疗总体反应的百分比改善的变化。
来自 5 个中东国家的 602 名患者入组。治疗 2 周后，地氯雷他定显著（P < 0.0001）降低了个体鼻部和总眼部症状评分以及 TSS 的平均评分。治疗后，鼻塞的 PNIF 测量值显著（P < 0.0001）改善。大多数患者获得了 AR 症状的完全（38.1%）或显著（47.2%）缓解。有 2.2%的患者报告治疗失败。没有报告不良反应，也没有患者停止治疗。
大多数患者报告称，地氯雷他定 5mg/d 治疗 2 周可显著缓解症状。地氯雷他定对中东海湾地区的阿拉伯和亚洲 AR 患者有效。
